Core 4 Inhibitor Development Service at CD BioGlyco

The addition of N-acetylgalactosamine (GalNAc) to the serine or threonine of a polypeptide initiates O-glycosylation, which is further refined at the C3 or C6 position to form the core O-linked glycan structure. The core 4 structure is achieved by adding N-acetylglucosamine (GlcNAc) to the 6 bits of GalNAc in the core 3 structure. This process is catalyzed by core 4 β1,6-GlcNAc transferase. CD BioGlyco has various Glycosylation Inhibitor Development Solutions, and we provide a one-stop core 4 inhibitor development service.

• Inhibitor design and synthesis service

CD BioGlyco uses computer-aided drug design and organic synthesis technology to design and synthesize compounds with core 4 inhibitory activity.

• High-throughput screening (HTS) service

CD BioGlyco uses an efficient HTS means to identify candidates with core 4 inhibitory activity through large-scale screening of compound libraries. We have developed some inhibitors of core 4 β1,6-GlcNAc transferase, such as O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate (PUGNAC), which is a competitive small molecule compound that interferes with the activity of core 4 enzymes, thereby inhibiting the transfer of β1,6-GlcNAc.

• Structural optimization service

CD BioGlyco uses medicinal chemistry methods to optimize the structure of the screened candidates to improve their activity, selectivity, and pharmacokinetic properties.

• Activity assessment service

CD BioGlyco uses a variety of in vitro and cellular assays to evaluate the inhibitory effect of candidates on core 4 and determine their inhibitory mechanisms.

• Pharmacokinetic research service

CD BioGlyco provides pharmacokinetic evaluation services on drug metabolism, absorption, distribution, and excretion of candidates to determine the properties and potential toxicity of the candidates, including studies on in vitro metabolic stability, cell permeability, and in vivo kinetics.

Fig.1 Core 4 inhibitor development service. (CD BioGlyco)

Publication

Technology: Liquid chromatography analysis

Journal: Journal of Biological Chemistry

IF: 5.485

Published: 1998

Results: The authors explored the reasons for the changes in O-GlcNAc levels observed in HT29 cells. The results showed that the increase in O-GlcNAc levels induced by PUGNAc is due to the direct inhibition of O-GlcNAcase in these cells. PUGNAc is a competitive inhibitor of O-GlcNAcase and it has a significant impact on the activity of O-GlcNAcase in HT29 cells. The inhibited concentration dependence was closely related to the concentration required to achieve maximum effect in cells.

Fig.2 Schematic diagram of PUGNAc inhibiting O-GlcNAcase. (Haltiwanger, et al., 1998)

Applications

• Immune regulation: Core 4 plays an important regulatory role in immune cells. The development of core 4 inhibitors is used to interfere with immune cell activation and inflammatory responses and may have potential applications in the research of autoimmune diseases, organ transplant rejection, etc.
• Nervous system diseases: Core 4 is involved in the regulation of multiple signaling pathways in the nervous system, such as neuronal development, synaptic plasticity, and the development of neurodegenerative diseases. The development of core 4 inhibitors may help research the pathological processes of neurological diseases.
• Cardiovascular diseases: Core 4 has an important impact on the functions of the heart and vascular system, and is involved in regulating physiological processes such as myocardial contraction and vasodilation. Developing core 4 inhibitors could impact the development of cardiovascular diseases, such as heart failure and hypertension.

Advantages

• CD BioGlyco designs and synthesizes compounds with good activity and selectivity for core 4 targets, and performs professional structural optimization.
• Our scientists evaluate the activity, selectivity, and sample properties of candidate compounds and provide detailed reports and interpretation of results to help our clients make informed decisions.
• CD BioGlyco has efficient project management capabilities to ensure that core 4 inhibitor development projects are completed within a reasonable timeframe and deliver high-quality results.

CD BioGlyco is a biotechnology company with strong scientific research capabilities. We have established advanced laboratory facilities, HTS means, and drug design tools to conduct a rapid and effective core 4 inhibitor development process. Please feel free to contact us if you are interested in our inhibitor development service.